A Long-term Monitoring Study to Evaluate the Persistence of Direct Antiviral (DAA) Treatment Resistant Mutations or the Durability of Sustained Virological Response (SVR) in Patients Treated With DAA Containing Regimens for Chronic Hepatitis C Infections (CHC)
Phase of Trial: Phase II
Latest Information Update: 14 Mar 2016
At a glance
- Drugs Mericitabine (Primary) ; Antivirals; Boceprevir; Danoprevir; Setrobuvir; Telaprevir
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Roche
- 10 Mar 2016 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 31 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.